This compound is a potent and selective JAK1 inhibitor used in pharmaceutical formulations targeting inflammatory and autoimmune diseases. It modulates Janus kinase pathways involved in cytokine signaling, cell proliferation, and immune response. Commonly investigated and approved for treatments of rheumatoid arthritis due to its ability to suppress pro-inflammatory cytokine signaling, reducing joint inflammation, swelling, and damage. Also under evaluation for other autoimmune conditions such as ulcerative colitis and Crohn's disease. Demonstrates high efficacy in clinical trials with favorable pharmacokinetic properties, suitable for oral administration.